The patients view on genetics and functional imaging for precision medicine: a willingness-to-pay analysis

2022 ◽  
Author(s):  
Kerstin Clasen ◽  
Cihan Gani ◽  
Christopher Schroeder ◽  
Olaf Riess ◽  
Daniel Zips ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Personalized Medicine ◽  
Willingness To Pay ◽  
Precision Medicine ◽  
Cancer Patients ◽  
Functional Imaging ◽  
Treatment Success ◽  
Diagnostic Modality ◽  
Ethical Concerns

Purpose: Willingness-to-pay (WTP) analyses can support allocation processes considering the patients preferences in personalized medicine. However, genetic testing especially might imply ethical concerns that have to be considered. Methods: A WTP questionnaire was designed to compare preferences for imaging and genetic testing in cancer patients and to evaluate potential ethical concerns. Results: Comparing the options of imaging and genetics showed comparable WTP values. Ethical concerns about genetic testing seemed to be minor. Treatment success was the top priority irrespective of the diagnostic modality. In general, the majority of patients considered personalized medicine to be beneficial. Conclusion: Most patients valued personalized approaches and rated the benefits of precision medicine of overriding importance irrespective of modality or ethical concerns.

Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk

2007 ◽  
Vol 4 (3) ◽  
pp. 341-350 ◽  
Author(s):  
Stephanie L Van Bebber ◽  
Su-Ying Liang ◽  
Kathryn A Phillips ◽  
Deborah Marshall ◽  
Judith Walsh ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Genetic Testing ◽  
Personalized Medicine ◽  
Cancer Risk ◽  
Willingness To Pay ◽  
Colorectal Cancer Risk

scholarly journals Willingness to Pay for Cancer Genetic Testing in a Tertiary Healthcare Centre

2021 ◽  
Vol 20 (3) ◽  
Author(s):  
Aizuddin AN ◽  
Syed Rusli SAS ◽  
Ramdzan AR ◽  
Syed Omar SA ◽  
Mahmud Z ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Willingness To Pay ◽  
Cancer Patients ◽  
Family Members ◽  
Cancer Genetic ◽  
Healthcare Centre ◽  
Factors Associated ◽  
Personal Benefit ◽  
Tertiary Healthcare ◽  
Knowledge And Attitude

INTRODUCTION: Increasing use of predictive genetic testing to address hereditary cancer risk has been commonly assessed by cost sharing practices. Little is known about how demographics, knowledge, attitude and practices may influence these individuals’ willingness to pay for cancer genetic testing. The objective of this research was to determine factors associated with willingness to pay for cancer genetic testing. MATERIALS AND METHODS: A self-administered questionnaire was distributed to 175 respondents in the oncology and day care unit in one of tertiary healthcare centre. The respondents comprised cancer patients, their family members and the community. RESULTS: A total of 117 (66.9%) participants were willing to pay for cancer genetic testing. Ninety three (79.5%) of respondents were willing to pay from their own pocket with a mean of MYR1201.77 (SD976.72) and 95 (54.3%) respondents were willing to pay, shared with insurance. There were significant associations between willingness to pay with status of respondent as patients or family members or community, gender, race, educational level, income, knowledge and attitude. CONCLUSION: This is the first study to evaluate factors associated with willingness to pay not only among cancer patients but also their family members and the community. These findings reveal that majority of respondents believe there is valuable personal benefit based on genetic risk information and they are willing to pay for it.

scholarly journals Awareness, knowledge, perceived benefits, and barriers regarding precision medicine and willingness to participate in a national registry: Comparison of cancer patients and the general population (Preprint)

2019 ◽  
Author(s):  
Mangyeong Lee ◽  
Juhee Cho ◽  
Sun-Young Kong ◽  
JunghHee Yoon ◽  
Danbee Kang ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
General Population ◽  
Precision Medicine ◽  
Cancer Patients ◽  
National Registry ◽  
Willingness To Participate ◽  
Perceived Benefits ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Area Of Interest

BACKGROUND Precision medicine (PM) is a growing area of interest in cancer care. Although the terms ‘precision medicine’ and ‘personalized medicine’ are used interchangeably, the former may be new both to cancer patients and the general population. Most previous studies evaluated peoples’ attitudes towards genetic testing as a part of personalized medicine and included a single stakeholder, either patients or the general population. Few studies have evaluated cancer patients’ knowledge and perception regarding PM. OBJECTIVE To evaluate cancer patients’ awareness, knowledge, as well as perceived benefits and barriers regarding PM, and their willingness to participate in a national registry for PM, in comparison to those of the general population. METHODS We conducted a cross-sectional survey on 1,500 consecutive cancer patients enrolled at two university-based cancer hospitals in Seoul, Korea; 1,500 people who were representative of the Korean population were enrolled as controls. Multivariable logistic regression was conducted to identify the factors associated with a willingness to participate in a national registry for PM. RESULTS : In the total population, 20.0% of the cancer patients had heard of PM and 35.1% were able to accurately define it. Cancer patients were three times likelier to express a willingness to participate in a national registry for PM than the general population (95% confidence interval [CI], 2.47-3.61). Participants who had heard of PM (cancer patients: adjusted odds ratio (aOR) = 1.40, 95% CI, 1.00-1.95; general population: aOR = 2.04, 95% CI, 1.62-2.56) and who had a more positive perception of the PM-related benefits (cancer patients: aOR = 2.48, 95% CI, 1.88-3.27; general population: aOR = 1.34, 95% CI, 1.05-1.71) were likelier to be willing to participate in a national registry for PM. CONCLUSIONS While PM is gaining importance in clinical settings, a majority of cancer patients are not well-informed about it. Nevertheless, the patients in our study perceived PM as being associated with various benefits and showed a willingness to participate in a national registry for PM. Considerable efforts need to be taken to educate the public and advocate participation in studies on PM

Cancer Biomarker Discovery for Precision Medicine: New Progress

2020 ◽  
Vol 26 (42) ◽  
pp. 7655-7671 ◽  
Author(s):  
Jinfeng Zou ◽  
Edwin Wang
Keyword(s):  
Precision Medicine ◽  
Cancer Patients ◽  
Clinical Application ◽  
Liquid Biopsy ◽  
Biomarker Discovery ◽  
Deep Understanding ◽  
Genetic Mutation ◽  
Data Driven ◽  
Novel Approaches ◽  
Functional Biomarkers

Background: Precision medicine puts forward customized healthcare for cancer patients. An important way to accomplish this task is to stratify patients into those who may respond to a treatment and those who may not. For this purpose, diagnostic and prognostic biomarkers have been pursued. Objective: This review focuses on novel approaches and concepts of exploring biomarker discovery under the circumstances that technologies are developed, and data are accumulated for precision medicine. Results: The traditional mechanism-driven functional biomarkers have the advantage of actionable insights, while data-driven computational biomarkers can fulfill more needs, especially with tremendous data on the molecules of different layers (e.g. genetic mutation, mRNA, protein etc.) which are accumulated based on a plenty of technologies. Besides, the technology-driven liquid biopsy biomarker is very promising to improve patients’ survival. The developments of biomarker discovery on these aspects are promoting the understanding of cancer, helping the stratification of patients and improving patients’ survival. Conclusion: Current developments on mechanisms-, data- and technology-driven biomarker discovery are achieving the aim of precision medicine and promoting the clinical application of biomarkers. Meanwhile, the complexity of cancer requires more effective biomarkers, which could be accomplished by a comprehensive integration of multiple types of biomarkers together with a deep understanding of cancer.

scholarly journals Identification of Novel Mutations in Colorectal Cancer Patients Using AmpliSeq Comprehensive Cancer Panel

2021 ◽  
Vol 11 (6) ◽  
pp. 535
Author(s):  
Bader Almuzzaini ◽  
Jahad Alghamdi ◽  
Alhanouf Alomani ◽  
Saleh AlGhamdi ◽  
Abdullah A. Alsharm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Personalized Medicine ◽  
Cancer Patients ◽  
Biomarker Discovery ◽  
Local Population ◽  
Network Analyses ◽  
Functional Perspective ◽  
Novel Variants ◽  
Colorectal Cancer Patients ◽  
Cancer Panel

Biomarker discovery would be an important tool in advancing and utilizing the concept of precision and personalized medicine in the clinic. Discovery of novel variants in local population provides confident targets for developing biomarkers for personalized medicine. We identified the need to generate high-quality sequencing data from local colorectal cancer patients and understand the pattern of occurrence of variants. In this report, we used archived samples from Saudi Arabia and used the AmpliSeq comprehensive cancer panel to identify novel somatic variants. We report a comprehensive analysis of next-generation sequencing results with a coverage of >300X. We identified 466 novel variants which were previously unreported in COSMIC and ICGC databases. We analyzed the genes associated with these variants in terms of their frequency of occurrence, probable pathogenicity, and clinicopathological features. Among pathogenic somatic variants, 174 were identified for the first time in the large intestine. APC, RET, and EGFR genes were most frequently mutated. A higher number of variants were identified in the left colon. Occurrence of variants in ERBB2 was significantly correlated with those of EGFR and ATR genes. Network analyses of the identified genes provide functional perspective of the identified genes and suggest affected pathways and probable biomarker candidates. This report lays the ground work for biomarker discovery and identification of driver gene mutations in local population.

Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany

2021 ◽  
Author(s):  
Albrecht Stenzinger ◽  
Anders Edsjö ◽  
Carolin Ploeger ◽  
Mikaela Friedman ◽  
Stefan Fröhling ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Precision Medicine ◽  
Genomic Medicine

scholarly journals Personalized Medicine: Recent Progress in Cancer Therapy

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 242
Author(s):  
Ann Hoeben ◽  
Elbert A. J. Joosten ◽  
Marieke H. J. van den Beuken-van Everdingen
Keyword(s):  
Cancer Therapy ◽  
Personalized Medicine ◽  
Precision Medicine ◽  
Recent Progress ◽  
Tumor Treatment ◽  
Treatment And Prevention

Personalized medicine (PM) or precision medicine in oncology is an emerging approach for tumor treatment and prevention that takes into account inter- and intra-tumor variability in genes, tumor (immune) environment, and lifestyle and morbidities of each person diagnosed with cancer [...]

Sign in / Sign up

Export Citation Format

Share Document